Zymeworks Inc.
$27.85
▼
-0.54%
2026-04-21 10:27:01
www.zymeworks.com
NMS: ZYME
Explore Zymeworks Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.98 B
Current Price
$27.85
52W High / Low
$28.49 / $10.86
Stock P/E
—
Book Value
$3.6
Dividend Yield
—
ROCE
-30.42%
ROE
-26.72%
Face Value
—
EPS
$-1.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
264
Beta
1.2
Debt / Equity
6.8
Current Ratio
5.88
Quick Ratio
5.88
Forward P/E
33.43
Price / Sales
18.46
Enterprise Value
$1.73 B
EV / EBITDA
-20.4
EV / Revenue
16.33
Rating
Strong Buy
Target Price
$40.08
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
| 2. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 3. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
| 4. | Sarepta Therapeutics, Inc. | $21.42 | — | $2.24 B | — | -29.18% | -53.47% | $64.8 / $10.42 | $10.87 |
| 5. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 6. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 7. | BridgeBio Oncology Therapeutics, Inc. | $9.26 | 158.62 | $748.31 M | — | -35.28% | -48.23% | $14.87 / $8.08 | $5.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.52 M | 27.61 M | 48.73 M | 27.11 M | 31.03 M | — |
| Operating Profit | -44.12 M | -22.06 M | -0.62 M | -25.63 M | -22.23 M | — |
| Net Profit | -41.21 M | -19.6 M | 2.32 M | -22.64 M | -23.51 M | — |
| EPS in Rs | -0.56 | -0.27 | 0.03 | -0.31 | -0.32 | -0.39 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 105.97 M | 76.3 M | 76.01 M | 412.48 M |
| Operating Profit | -92.53 M | -119.82 M | -138.01 M | 130.49 M |
| Net Profit | -81.13 M | -122.69 M | -118.67 M | 124.34 M |
| EPS in Rs | -1.1 | -1.66 | -1.61 | 1.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 346.53 M | 463.09 M | 580.88 M | 648.73 M |
| Total Liabilities | 78.03 M | 124.32 M | 116.07 M | 155.77 M |
| Equity | 268.5 M | 338.77 M | 464.81 M | 492.96 M |
| Current Assets | 248.77 M | 300.45 M | 412.93 M | 544.71 M |
| Current Liabilities | 42.32 M | 88.29 M | 55.76 M | 95.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -33.01 M | -110.06 M | -118.32 M | 144.11 M |
| Investing CF | 26.66 M | 38.76 M | -207.25 M | -53.85 M |
| Financing CF | -18.56 M | -20.44 M | 81.87 M | 108.58 M |
| Free CF | -35.36 M | -113.12 M | -122.4 M | 130.98 M |
| Capex | -2.35 M | -3.07 M | -4.08 M | -13.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 0.38% | -81.57% | — | — |
| Earnings Growth % | -3.39% | -195.44% | — | — |
| Profit Margin % | -160.8% | -156.13% | 30.14% | — |
| Operating Margin % | -157.03% | -181.56% | 31.63% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -142.36% | -158.79% | 34.54% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.